HARBIN, China, Sept. 2 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ('China Sky One Medical' or 'the Company') (AMEX: CSY), a leading fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China ('PRC'), today announced that it has received approval to list its common stock on the NASDAQ Global Market.

China Sky One expects to start trading on the NASDAQ Global Market on September 15, 2008, and that the last day of trading on the American Stock Exchange ('AMEX') will be September 12, 2008. The trading symbol for China Sky One's common stock on the NASDAQ Global Market will be 'CSKI'. The Company primarily sells its products in the People's Republic of China (PRC).

'We are very excited to list on NASDAQ and consider the change to be a significant milestone in China Sky One's development as a U.S. public company,' commented Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One. 'We are confident that the listing on NASDAQ will allow us to further enlarge our investor base and increase both our liquidity and visibility in the investment community.'

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ('TDR') and Harbin First Bio- Engineering Company Limited ('First'), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as 'believe,' 'expect,' 'may,' 'will,' 'should,' 'project,' 'plan,' 'seek,' 'intend,' or 'anticipate' or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:
    Company Contact:
     Mr. Yu-Bo Hao, Board Secretary
     China Sky One Medical, Inc.
     Tel:   +86-0451-53994069
     Email: china_sky_one@yahoo.cn
    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:      +1-646-213-1915
     Email:    crocker.coulson@ccgir.com
     Web site: http://www.ccgir.com
     Mr. Richard Micchelli, Financial Writer
     CCG Investor Relations
     Tel:      +1-646-454-4516
     Email:    richard.micchelli@ccgir.com
     Web site: http://www.ccgir.com

SOURCE China Sky One Medical, Inc.